
0:00
11:35
Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.
Related Content:
More episodes from "Healthy Dialogue"



Don't miss an episode of “Healthy Dialogue” and subscribe to it in the GetPodcast app.








